MX2022000128A - Desarrollo de clasificadores para estratificar pacientes. - Google Patents

Desarrollo de clasificadores para estratificar pacientes.

Info

Publication number
MX2022000128A
MX2022000128A MX2022000128A MX2022000128A MX2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A
Authority
MX
Mexico
Prior art keywords
responsive
subjects
developing classifiers
stratifying patients
developing
Prior art date
Application number
MX2022000128A
Other languages
English (en)
Inventor
Susan Ghiassian
Theodore R Mellors
Marc Santolini
Asher Ameli
Nancy Schoenbrunner
Viatcheslav R Akmaev
Keith J Johnson
Original Assignee
Scipher Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipher Medicine Corp filed Critical Scipher Medicine Corp
Publication of MX2022000128A publication Critical patent/MX2022000128A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se presentan sistemas y métodos para desarrollar clasificadores útiles para predecir la respuesta a tratamientos particulares en la presente. Por ejemplo, en algunas formas de realización, la presente descripción proporciona un método para tratar a sujetos que padecen un trastorno autoinmunitario, que comprende el método una etapa de: administrar una terapia anti-TNF a sujetos que se ha determinado que responden a través de un clasificador establecido para distinguir entre sujetos previos receptivos y no receptivos en una cohorte que ha recibido la terapia anti-TNF.
MX2022000128A 2019-06-27 2020-06-26 Desarrollo de clasificadores para estratificar pacientes. MX2022000128A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962867853P 2019-06-27 2019-06-27
US201962882402P 2019-08-02 2019-08-02
US202062965486P 2020-01-24 2020-01-24
PCT/US2020/039991 WO2020264426A1 (en) 2019-06-27 2020-06-26 Developing classifiers for stratifying patients

Publications (1)

Publication Number Publication Date
MX2022000128A true MX2022000128A (es) 2022-04-27

Family

ID=74061318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000128A MX2022000128A (es) 2019-06-27 2020-06-26 Desarrollo de clasificadores para estratificar pacientes.

Country Status (11)

Country Link
US (4) US11195595B2 (es)
EP (1) EP3990656A4 (es)
JP (1) JP2022541125A (es)
KR (1) KR20220044720A (es)
CN (1) CN114402084A (es)
AU (1) AU2020308906A1 (es)
CA (1) CA3145237A1 (es)
GB (1) GB2603294A (es)
IL (1) IL289304A (es)
MX (1) MX2022000128A (es)
WO (1) WO2020264426A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
KR20220044720A (ko) 2019-06-27 2022-04-11 사이퍼 메디슨 코퍼레이션 환자를 계층화하기 위한 분류기의 개발
US11430575B2 (en) * 2020-11-13 2022-08-30 Specialty Diagnostic (SDI) Laboratories, Inc. Systems and methods for a data driven disease test result prediction
GB2622147A (en) * 2021-03-19 2024-03-06 Scipher Medicine Corp Methods of classifying and treating patients
US20220399092A1 (en) * 2021-06-10 2022-12-15 Rajant Health Inc. Ai-enabled health platform
CA3223856A1 (en) * 2021-06-22 2022-12-29 Susan GHIASSIAN Methods and systems for therapy monitoring and trial design
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies
WO2024081737A1 (en) * 2022-10-12 2024-04-18 Exagen Inc. Biomarker selection for machine learning enabled prediction of treatment response
CN116312796B (zh) * 2022-12-27 2023-11-14 江苏先声医学诊断有限公司 一种基于期望最大化算法的宏基因组丰度估计方法及系统

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP2161348A1 (en) 2005-09-27 2010-03-10 Source MDX Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2007089303A2 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
SG182183A1 (en) * 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US7863021B2 (en) 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009102957A2 (en) 2008-02-14 2009-08-20 The Johns Hopkins University Methods to connect gene set expression profiles to drug sensitivity
US20110059445A1 (en) 2008-03-28 2011-03-10 Paul Rutgeerts Mucosal gene signatures
EP2326731B1 (en) 2008-08-25 2013-11-13 Janssen Biotech, Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
WO2010025961A2 (en) 2008-09-03 2010-03-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Computer implemented model of biological networks
CA2737485A1 (en) 2008-10-10 2010-04-15 Mount Sinai Hospital Methods for classifying samples based on network modularity
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
EP2488659B1 (en) 2009-10-15 2019-12-11 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring inflammatory disease activity
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
CN110322924A (zh) 2010-04-29 2019-10-11 加利福尼亚大学董事会 利用关于基因组模型的数据集成的途径识别方法(paradigm)
WO2012066536A2 (en) 2010-11-16 2012-05-24 Prediguard Transcriptome signatures discriminate etanercept-treated rheumatoid arthritis (ra) patients according to their response or refractory status
US20130040835A1 (en) 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CN103649336A (zh) * 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
EP2900695B1 (en) 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
WO2014068124A1 (en) 2012-11-05 2014-05-08 Diagnoplex Sa Biomarker combinations for colorectal tumors
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
WO2014135668A1 (de) 2013-03-08 2014-09-12 Universität Leipzig Verfahren und kit zur zytokinanalyse aus einer menschlichen vollblutprobe
WO2014186761A2 (en) 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
US20160162657A1 (en) 2013-07-08 2016-06-09 Northeastern University Methods For Identifying Complex Disease Subtypes
US9387246B2 (en) 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
US20160232279A1 (en) 2013-09-23 2016-08-11 Northeastern University System and Methods for Disease Module Detection
CA2943821A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US9753041B2 (en) 2014-04-21 2017-09-05 Univeristy Of South Florida Salivary inflammatory biomarkers associated with glycemic control and oral health
WO2016063204A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
WO2016088068A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
EP3337465B1 (en) 2015-08-21 2021-11-24 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
US10018637B2 (en) 2015-10-06 2018-07-10 Celgene International Ii Sarl Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
EP3165928B1 (en) 2015-11-06 2019-01-09 Promise Advanced Proteomics A method for quantifying anti-tnf antibodies
WO2017083564A1 (en) 2015-11-11 2017-05-18 Northeastern University Methods and systems for profiling personalized biomarker expression perturbations
US20170145501A1 (en) 2015-11-20 2017-05-25 Lasse Folkersen Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3440579A4 (en) 2015-11-24 2020-03-25 Klaritos, Inc. INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
AU2017281039A1 (en) 2016-06-20 2019-01-24 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
WO2019018440A1 (en) 2017-07-17 2019-01-24 The Broad Institute, Inc. HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS
US20190287644A1 (en) 2018-02-15 2019-09-19 Northeastern University Correlation Method To Identify Relevant Genes For Personalized Treatment Of Complex Disease
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
US20200303078A1 (en) 2019-03-22 2020-09-24 Inflammatix, Inc. Systems and Methods for Deriving and Optimizing Classifiers from Multiple Datasets
EP3948872A4 (en) 2019-03-28 2023-04-26 Phase Genomics Inc. SEQUENCING KARYOTYPING SYSTEMS AND METHODS
KR20220044720A (ko) 2019-06-27 2022-04-11 사이퍼 메디슨 코퍼레이션 환자를 계층화하기 위한 분류기의 개발
KR20240018404A (ko) 2020-09-01 2024-02-13 사이퍼 메디슨 코퍼레이션 항-tnf 요법에 대한 반응을 예측하기 위한 방법 및 시스템
GB2622147A (en) 2021-03-19 2024-03-06 Scipher Medicine Corp Methods of classifying and treating patients

Also Published As

Publication number Publication date
GB2603294A (en) 2022-08-03
EP3990656A1 (en) 2022-05-04
CN114402084A (zh) 2022-04-26
WO2020264426A1 (en) 2020-12-30
US11783913B2 (en) 2023-10-10
US20220101946A1 (en) 2022-03-31
US11456056B2 (en) 2022-09-27
US11195595B2 (en) 2021-12-07
US20230386606A1 (en) 2023-11-30
US20220375541A1 (en) 2022-11-24
US20210280271A1 (en) 2021-09-09
EP3990656A4 (en) 2023-12-06
GB202119148D0 (en) 2022-02-16
AU2020308906A1 (en) 2022-02-03
CA3145237A1 (en) 2020-12-30
KR20220044720A (ko) 2022-04-11
IL289304A (en) 2022-02-01
JP2022541125A (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2022000128A (es) Desarrollo de clasificadores para estratificar pacientes.
MX2023010970A (es) Metodos de clasificacion y tratamiento de pacientes.
Kimball et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
Langley et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2018003376A (es) Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
MX2007004079A (es) Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
MX2022002244A (es) Metodo para identificar respondedores a degradantes de smarca2/4.
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
MX2023006039A (es) Celulas inmunes defectuosas para suv39h1.
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX2023002446A (es) Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.
Chaabna et al. Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?
MX2020013535A (es) Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
MX2023008115A (es) Terapia con receptores quiméricos.
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
Evoli et al. Italian recommendations for Lambert–Eaton myasthenic syndrome (LEMS) management
Matas et al. Systemic regulatory T cells and IL-6 as prognostic factors for anatomical improvement of uveitic macular edema
Morin et al. Treatment with chemotherapy and cognitive functioning in older adult cancer survivors
WO2023150731A3 (en) Systems and methods for predicting response to anti-tnf therapies
El Samahy et al. Circulating CD 4+ CD 25highFoxP3+ T‐regulatory cells in patients with atopic dermatitis after narrowband‐ultraviolet B phototherapy
MX2017012828A (es) Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne.
Sung et al. The immunological association between alopecia areata and respiratory diseases: a systematic review
WO2019243898A3 (en) Methods for improving response to anti-lif antibody treatment in individuals with cancer